Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and Cancer of Cervix

cyc 202 has been researched along with Cancer of Cervix in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arisan, ED; Coker-Gurkan, A; Obakan-Yerlikaya, P; Ozfiliz-Kilbas, P; Palavan-Unsal, N; Sarikaya, B; Temizci, B1
Hajek, SB; Kramer, MP; Krystof, V; Pickem, C; Wandl, S; Wesierska-Gadek, J1
Borza, A; Komina, O; Krystof, V; Maurer, M; Walzi, E; Wandl, S; Wesierska-Gadek, J1
Borza, A; Komina, O; Maurer, M; Wesierska-Gadek, J1
Chen, MC; Chiang, MC; Hsu, FN; Kuo, HS; Lin, H; Lo, MJ; You, SC1
Carminatti, H; Casas, O; Cruz, M; Fernandez, A; Idoyaga Vargas, V; Settembrini, L; Siden, A; Vita, MF; Vitali, L; Yakisich, JS1

Other Studies

6 other study(ies) available for cyc 202 and Cancer of Cervix

ArticleYear
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells.
    Molecular biology reports, 2018, Volume: 45, Issue:5

    Topics: Adenine; Autophagy; Cell Proliferation; Cell Survival; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Protein Kinase Inhibitors; Purines; Reactive Oxygen Species; Roscovitine; Time Factors; Unfolded Protein Response; Uterine Cervical Neoplasms

2018
Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
    Journal of cellular biochemistry, 2008, Dec-01, Volume: 105, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; HeLa Cells; Humans; Purines; Roscovitine; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms

2008
Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.
    Journal of cellular biochemistry, 2009, Apr-01, Volume: 106, Issue:5

    Topics: Cell Cycle; Culture Media, Serum-Free; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Female; G1 Phase; HeLa Cells; Humans; Purines; Roscovitine; Uterine Cervical Neoplasms

2009
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
    Acta biochimica Polonica, 2009, Volume: 56, Issue:3

    Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Female; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Immunoblotting; Phosphorylation; Protein Kinase Inhibitors; Purines; Roscovitine; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms

2009
The role of Cdk5 in retinoic acid-induced apoptosis of cervical cancer cell line.
    The Chinese journal of physiology, 2009, Feb-28, Volume: 52, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase 5; Female; G1 Phase; Growth Inhibitors; HeLa Cells; Humans; Purines; RNA, Small Interfering; Roscovitine; Tretinoin; Uterine Cervical Neoplasms

2009
Roscovitine inhibits ongoing DNA synthesis in human cervical cancer.
    Cancer letters, 2002, Jun-06, Volume: 180, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Cyclin-Dependent Kinases; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Middle Aged; Purines; Roscovitine; Time Factors; Uterine Cervical Neoplasms

2002